Drug
Yl242
Yl242: highest development phase Phase 1/2, developed by MediLink Therapeutics (Suzhou) Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MediLink Therapeutics (Suzhou) Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| YL242 NCT07197827 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Yl242 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.